Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo

Biochemical and Biophysical Research Communications

Volumn 370, Issue 4, 2008, Pages 634-640

  Schmidt, Robert J ^a   Beyer, Thomas P ^a   Bensch, William R ^a   Qian, Yue Wei ^a   Lin, Aiming ^a   Kowala, Mark ^a   Alborn, William E ^a   Konrad, Robert J ^a   Cao, Guoqing ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

LDL; LDLR; PCSK9

Indexed keywords

KEXIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE 1; SUBTILISIN;

ADIPOSE TISSUE; ARTICLE; CONTROLLED STUDY; ENDOCYTOSIS; HUMAN; HUMAN CELL; KIDNEY PARENCHYMA; LIVER; LUNG PARENCHYMA; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SECRETION; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; CATALYSIS; CHOLESTEROL, LDL; HUMANS; INJECTIONS, INTRAVENOUS; LIVER; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, LDL; RECOMBINANT PROTEINS; SERINE ENDOPEPTIDASES;

MUS;

EID: 46349103159     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.04.004     Document Type: Article

References (23)

1. Seidah N.G., and Prat A. The proprotein convertases are potential targets in the treatment of dyslipidemia. J. Mol. Med. 85 (2007) 685-696 (Epub 2007 March 10)
2. Horton J.D. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem. Sci. 32 (2007) 71-77 (Epub 2007 January)
3. Seidah N.G., Benjannet S., Wickham L., Marcinkiewicz J., Jasmin S.B., Stifani S., Basak A., Prat A., and Chretien M. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. USA 100 (2003) 928-933 (Epub 2003 January 27)
4. Benjannet S., Rhainds D., Essalmani R., Mayne J., Wickham L., Jin W., Asselin M.C., Hamelin J., Varret M., Allard D., Trillard M., Abifadel M., Tebon A., Attie A.D., Rader D.J., Boileau C., Brissette L., Chretien M., Prat A., and Seidah N.G. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem. 279 (2004) 48865-48875 (Epub 2004 September 9)
5. Lagace T.A., Curtis D.E., Garuti R., McNutt M.C., Park S.W., Prather H.B., Anderson N.N., Ho Y.K., Hammer R.E., and Horton J.D. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J. Clin. Invest. 116 (2006) 2995-3005
6. Alborn W.E., Cao G., Careskey H.E., Qian Y.W., Subramaniam D.R., Davies J., Conner E.M., and Konrad R.J. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin. Chem. 53 (2007) 1814-1819 (Epub 2007 August 1)
7. Mayne J., Raymond A., Chaplin A., Cousins M., Kaefer N., Gyamera-Acheampong C., Seidah N.G., Mbikay M., Chretien M., and Ooi T.C. Plasma PCSK9 levels correlate with cholesterol in men but not in women. Biochem. Biophys. Res. Commun. 361 (2007) 451-456 (Epub 2007 July 18)
8. Careskey H.E., Davis R.A., Alborn W.E., Troutt J.S., Cao G., and Konrad R.J. Atorvastatin increases human serum levels of proprotein convertase subtilisin kexin type 9 (PCSK9). J. Lipid Res. 21 (2007) 21
9. Abifadel M., Varret M., Rabes J.P., Allard D., Ouguerram K., Devillers M., Cruaud C., Benjannet S., Wickham L., Erlich D., Derre A., Villeger L., Farnier M., Beucler I., Bruckert E., Chambaz J., Chanu B., Lecerf J.M., Luc G., Moulin P., Weissenbach J., Prat A., Krempf M., Junien C., Seidah N.G., and Boileau C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34 (2003) 154-156
10. Cohen J., Pertsemlidis A., Kotowski I.K., Graham R., Garcia C.K., and Hobbs H.H. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37 (2005) 161-165 (Epub 2005 January 16)
11. Cohen J.C., Boerwinkle E., Mosley Jr. T.H., and Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354 (2006) 1264-1272
12. Maxwell K.N., and Breslow J.L. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc. Natl. Acad. Sci. USA 101 (2004) 7100-7105 (Epub 2004 April 26)
13. Park S.W., Moon Y.A., and Horton J.D. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J. Biol. Chem. 279 (2004) 50630-50638 (Epub 2004 September 22)
14. Rashid S., Curtis D.E., Garuti R., Anderson N.N., Bashmakov Y., Ho Y.K., Hammer R.E., Moon Y.A., and Horton J.D. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc. Natl. Acad. Sci. USA 102 (2005) 5374-5379 (Epub 2005 April 1)
15. Qian Y.W., Schmidt R.J., Zhang Y., Chu S., Lin A., Wang H., Wang X., Beyer T.P., Bensch W.R., Li W., Ehsani M.E., Lu D., Konrad R.J., Eacho P.I., Moller D.E., Karathanasis S.K., and Cao G. Secreted proprotein convertase subtilisin/kexin-type 9 downregulates low-density lipoprotein receptor through receptor-mediated endocytosis. J. Lipid Res. 20 (2007) 20
16. Cunningham D., Danley D.E., Geoghegan K.F., Griffor M.C., Hawkins J.L., Subashi T.A., Varghese A.H., Ammirati M.J., Culp J.S., Hoth L.R., Mansour M.N., McGrath K.M., Seddon A.P., Shenolikar S., Stutzman-Engwall K.J., Warren L.C., Xia D., and Qiu X. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat. Struct. Mol. Biol. 14 (2007) 413-419 (Epub 2007 April 15)
17. Fisher T.S., Lo Surdo P., Pandit S., Mattu M., Santoro J.C., Wisniewski D., Cummings R.T., Calzetta A., Cubbon R.M., Fischer P.A., Tarachandani A., De Francesco R., Wright S.D., Sparrow C.P., Carfi A., and Sitlani A. PCSK9-dependent LDL receptor regulation: effects of pH and LDL. J. Biol. Chem. 10 (2007) 10
18. Zhang D.W., Lagace T.A., Garuti R., Zhao Z., McDonald M., Horton J.D., Cohen J.C., and Hobbs H.H. Binding of PCSK9 to EGF-A repeat of LDL receptor decreases receptor recycling and increases degradation. J. Biol. Chem. 23 (2007) 23
19. McNutt M.C., Lagace T.A., and Horton J.D. Catalytic activity is not required for secreted PCSK9 to reduce LDL receptors in HepG2 cells. J. Biol. Chem. 29 (2007) 29
20. Li J., Tumanut C., Gavigan J.A., Huang W.J., Hampton E.N., Tumanut R., Suen K.F., Trauger J.W., Spraggon G., Lesley S.A., Liau G., Yowe D., and Harris J.L. Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity. Biochem. J. 406 (2007) 203-207
21. Brown M.S., and Goldstein J.L. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc. Natl. Acad. Sci. USA 96 (1999) 11041-11048
22. Brown M.S., and Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science 232 (1986) 34-47
23. Kieft K.A., Bocan T.M., and Krause B.R. Rapid on-line determination of cholesterol distribution among plasma lipoproteins after high-performance gel filtration chromatography. J. Lipid Res. 32 (1991) 859-866